China's Pharma Giant Just Landed a $2.6B Deal with Novo Nordisk

Very Bullish · $600276.SS

What Happened

Hengrui Pharma licensed its oral GLP-1/GIP dual agonist HRS-1596 to Novo Nordisk for up to $2.6 billion, including $300 million upfront.

Bottom Line

Hengrui's innovative drug pipeline gains global recognition, reinforcing its growth story.

Free preview — more China A-share & HK research · About Us · Legal & Privacy